Grafapex, Trecondi(treosulfan)
Grafapex, Trecondi (treosulfan) is a small molecule pharmaceutical. Treosulfan was first approved as Trecondi on 2019-06-20. It has been approved in Europe to treat hematopoietic stem cell transplantation.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| therapeutics | D013812 |
| operative surgical procedures | D013514 |
Trade Name
FDA
EMA
Grafapex
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Treosulfan
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| GRAFAPEX | Medexus Pharmaceuticals | N-214759 RX | 2025-01-21 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| grafapex | New Drug Application | 2025-01-31 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
52 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 2 | 13 | 5 | 1 | — | 18 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | 8 | 5 | 1 | — | 12 |
| Lymphoid leukemia | D007945 | — | C91 | — | 3 | 3 | 1 | — | 6 |
| Immune system diseases | D007154 | — | D89.9 | — | — | — | 1 | — | 1 |
| Immunoproliferative disorders | D007160 | — | C88.9 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | — | D46 | 3 | 17 | 2 | — | — | 19 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 2 | 13 | 3 | — | — | 17 |
| Lymphoma | D008223 | — | C85.9 | — | 4 | 1 | — | — | 4 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 3 | 1 | — | — | 3 |
| Biphenotypic leukemia acute | D015456 | — | C95.0 | — | 2 | 1 | — | — | 2 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | 1 | — | — | 1 |
| Ewing sarcoma | D012512 | EFO_0000173 | — | — | — | 1 | — | — | 1 |
| Melanoma | D008545 | — | — | — | — | 1 | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | — | 1 | — | — | 1 |
| Ovarian epithelial carcinoma | D000077216 | — | — | — | — | 1 | — | — | 1 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Preleukemia | D011289 | — | — | 2 | 8 | — | — | — | 9 |
| Hematologic neoplasms | D019337 | — | — | 2 | 7 | — | — | — | 8 |
| Syndrome | D013577 | — | — | 1 | 7 | — | — | — | 7 |
| Myeloid leukemia | D007951 | — | C92 | — | 6 | — | — | — | 6 |
| Multiple myeloma | D009101 | — | C90.0 | 2 | 4 | — | — | — | 5 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | — | 4 | — | — | — | 4 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 1 | 4 | — | — | — | 4 |
| Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | — | 4 | — | — | — | 4 |
| Neoplasms | D009369 | — | C80 | 2 | 3 | — | — | — | 4 |
| Hodgkin disease | D006689 | — | C81 | — | 3 | — | — | — | 3 |
Show 46 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hematopoietic stem cell transplantation | D018380 | — | — | 1 | — | — | — | 1 | 2 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Treosulfan |
| INN | treosulfan |
| Description | Treosulfan is a methanesulfonate ester. |
| Classification | Small molecule |
| Drug class | antineoplastics, alkylating agents (methane sulfonate derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O |
Identifiers
| PDB | — |
| CAS-ID | 299-75-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL455186 |
| ChEBI ID | 82557 |
| PubChem CID | 9882105 |
| DrugBank | DB11678 |
| UNII ID | CO61ER3EPI (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,851 documents
View more details
Safety
Black-box Warning
Black-box warning for: Grafapex
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,423 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use